ERBB2 and neoplasm: In this regard, CT-0508, an anti-HER2 CAR-M, exhibited a favourable safety profile in a Phase I trial targeting recurrent or metastatic HER2+ tumours (NCT04660929) and was granted FDA Fast Track status in 2021.